Germany's Merck In Talks To Buy Cancer Drug Maker SpringWorks Therapeutics
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 11 2025
0mins
Source: Benzinga
Merck KGaA's Potential Acquisition: Merck KGaA confirmed ongoing discussions with SpringWorks Therapeutics, although no binding agreement has been reached and critical conditions remain unmet. The potential deal could enhance Merck's oncology portfolio and address revenue challenges from expiring drug patents.
SpringWorks Therapeutics Overview: SpringWorks' first product, Ogsiveo, is the only FDA-approved treatment for desmoid tumors, generating significant revenue. The company anticipates achieving profitability by mid-2026, supported by a strong cash position and upcoming product reviews.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
